In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/Wella

This article was originally published in The Rose Sheet

Executive Summary

Frankfurt court will hold hearing June 26 to assess case brought by hedge fund group Elliott Associates, a minority shareholder of Wella that is seeking to bring down Procter & Gamble's bid for the German company, a law firm for Elliott says. A ruling in favor of Elliott would find P&G's bid is prohibited according to German law, in which case "any and all contracts or legal acts carried out would be nullified," firm maintains. Directed to German regulatory authorities, Elliott's lawsuit maintains P&G's offering for Wella shares is too low. The group failed to get a preliminary injunction against P&G's bid last month. P&G's second tender period for accepting Wella shares ended June 20 (1"The Rose Sheet" June 2, 2003, p. 8)...

You may also be interested in...



Wella Integration To Proceed Regardless Of Offer Outcome, P&G Says

Procter & Gamble remains confident it will acquire outstanding shares of Wella during an additional two-week acceptance period beginning June 6, the company stated May 29, the day after its initial tender offer for the German hair care company closed

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel